Full-Time

Senior Manager

Advanced Process Development

Inspire Medical Systems

Inspire Medical Systems

1,001-5,000 employees

FDA-approved neurostimulation device for OSA

Compensation Overview

$140k - $185k/yr

+ Equity awards + Employee Stock Purchase Program

Minneapolis, MN, USA

In Person

Bachelor's

Category
Biology & Biotech (1)
Required Skills
Quality Assurance (QA)
Risk Management

Get referred to Inspire Medical Systems

See people who can refer or advise you

Requirements
  • A bachelor's degree in mechanical engineering, electrical engineering, biomedical engineering, manufacturing engineering, or a related technical field is required.
  • At least 8 years of engineering experience in medical devices, regulated manufacturing, automation, test systems, process development, or new product introduction environments is required.
  • At least 3 years of direct leadership experience with responsibility for technical teams, project execution, and cross-functional delivery is required.
  • Demonstrated experience supporting or leading new product development, design transfer, manufacturing process development, and production launch readiness is required.
  • Experience translating product requirements into manufacturing, equipment, test, electrical, mechanical, and software specifications is required.
  • Experience working with machine builders, automation suppliers, contract manufacturers, or external technical partners is required.
  • Strong understanding of medical device quality systems, design controls, process validation, risk management, and verification and validation practices is required.
  • Proven ability to build structure, align teams, resolve technical issues, and deliver results in a fast-paced, cross-functional environment is required.
  • Demonstrated ability to develop engineers, build technical capability, coach performance, and create career growth opportunities within an engineering organization is required.
Responsibilities
  • Create and lead an Advanced Process Development group dedicated to new product development projects and launch readiness.
  • Move engineering headcount dedicated to new products into the new structure and align the organization to launch execution and manufacturing readiness.
  • Lead, coach, and develop process development, test systems, and manufacturing engineering talent in support of new product commercialization.
  • Provide priorities, technical direction, and execution rhythm across cross-functional launch teams.
  • Develop and grow engineering talent by setting expectations, providing coaching and feedback, and building individual development plans.
  • Create growth opportunities for engineers through project ownership, technical problem-solving, cross-functional exposure, mentoring, and structured development assignments.
  • Build an engineering culture focused on accountability, technical excellence, collaboration, continuous improvement, and disciplined execution.
  • Lead design transfer activities after design freeze and move new products into stable, qualified manufacturing processes.
  • Partner with Product Design and Research and Development teams to understand critical product design requirements and their implications for manufacturing, test, and process capability.
  • Translate critical product requirements into manufacturing specifications, including electrical, mechanical, software, test method, equipment, and process requirements.
  • Drive technical alignment between product design intent, process capability, equipment design, and production readiness.
  • Ensure launch plans include process development milestones, risks, mitigations, validation requirements, and handoff criteria to Operations Engineering.
  • Partner with machine builders, automation providers, suppliers, and internal engineering resources to design and implement manufacturing equipment for new products.
  • Own the development of capable manufacturing and test systems that support launch quality, repeatability, throughput, and long-term process stability.
  • Qualify manufacturing processes and test systems before production release and handoff to Operations Engineering.
  • Drive process characterization, risk mitigation, equipment readiness, and validation planning in accordance with regulated medical device requirements.
  • Partner with Product Design, Operations Engineering, Quality, Regulatory, Supply Chain, and Program Management to ensure product launch plans are technically sound and execution-ready.
  • Serve as the primary bridge between product development and manufacturing operations for new product process readiness.
  • Identify design, equipment, test, process, and supplier risks that could impact launch timing, quality, cost, or manufacturability.
  • Transfer stable manufacturing processes to Operations Engineering with clear ownership, documentation, training, and performance expectations.
Desired Qualifications
  • Background in complex electromechanical systems, active implantable devices, electronics, software-enabled systems, or high-reliability medical devices.
  • Hands-on experience writing test protocols, qualification protocols, engineering reports, and process transfer documentation.
  • Experience scaling an advanced manufacturing, process development, new product introduction, or launch engineering function.
  • Strong systems thinking, structured problem-solving, communication, and stakeholder management skills.
Inspire Medical Systems

Inspire Medical Systems

View

Inspire Medical Systems develops and sells a minimally invasive implantable device for obstructive sleep apnea (OSA). Its lead product, the Inspire system, uses implanted neurostimulation to activate the hypoglossal nerve, which moves the tongue and other airway muscles to keep the airway open during sleep. Patients control the therapy with a small handheld remote. The system targets adults with moderate to severe OSA who cannot use or benefit consistently from CPAP. Unlike non-implant options, Inspire provides a hands-free, on-demand airway support during sleep and is the first FDA-approved neurostimulation treatment for OSA. The company differentiates itself by offering a clinically approved implantable alternative to CPAP, backed by a direct US sales force and a network in Europe. Its goal is to provide an effective, durable option for patients who struggle with CPAP, expanding access to neurostimulation therapy to improve sleep quality and health outcomes.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Golden Valley, Minnesota

Founded

2007

Get referred to Inspire Medical Systems

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • CMS proposed 2027 facility reimbursement increases for Inspire V on August 2026 filings.
  • Management raised 2026 revenue guidance to $835 million-$875 million after Q2 beat.
  • Project Horizon and Michael H. Carrel's board appointment sharpen access and execution focus.

What critics are saying

  • Coding confusion cut Q2 2026 revenue by $40 million and pressured 2026 guidance.
  • WISeR prior authorization and CPT 64582 modifier friction can delay adoption through 2026.
  • If reimbursement stays muddled until 2028, Inspire loses physician economics and growth leadership.

What makes Inspire Medical Systems unique

  • Only FDA-approved implanted neurostimulation therapy for moderate-to-severe OSA with CPAP failure.
  • 3 Tesla MRI compatibility expanded usability for implanted sleep-apnea patients in February 2026.
  • Direct U.S. sales and in-house reimbursement navigation create a specialized commercial moat.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

401(k) Retirement Plan

401(k) Company Match

Unlimited Paid Time Off

Tuition Reimbursement

Employee Assistance program

Employee Stock Purchase Plan

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Aug 20th, 2026
BrightSpring Health Services posts 23.9% revenue growth as Solventum and Inspire Medical face headwinds

BrightSpring Health Services stands out as a strong long-term healthcare investment, whilst Solventum and Inspire Medical Systems face headwinds, according to recent analysis. Healthcare stocks have surged 27.5% over the past six months, outperforming the S&P 500 by 16.2 percentage points. However, increased venture capital has intensified competition across the sector. BrightSpring, which provides home health care, hospice, and pharmacy services, has achieved 23.9% annual revenue growth over the past two years. Analysts forecast 14.1% revenue growth for the next 12 months. Conversely, Solventum faces weak demand with flat revenue expected, whilst its free cash flow margin has declined 18.2 percentage points over five years. Inspire Medical Systems confronts a forecasted revenue decline of 3.5% for the upcoming year.

Yahoo Finance
Aug 7th, 2026
Inspire Medical shares surge 28.1% after Q2 earnings beat and raised 2026 guidance

Inspire Medical Systems shares have risen 28.1% in the past month following a second-quarter earnings beat and raised 2026 guidance. The company reported adjusted earnings of 14 cents per share, surpassing consensus estimates for a 22-cent loss, whilst revenues of $200.6 million exceeded expectations despite declining 7.6% year over year. Management increased its 2026 revenue outlook to $835–875 million and raised adjusted earnings guidance to $1.05–$1.45 per share. The Zacks consensus estimate for 2026 earnings increased 34.7% over the past four weeks. However, coding challenges and prior authorisation programmes reduced second-quarter revenues by approximately $40 million. Management expects a full-year impact of $120–130 million and forecasts an 8–10% revenue decline in the third quarter.

Yahoo Finance
Aug 4th, 2026
Inspire Medical launches Project Horizon with $30M reinvestment to boost patient access amid reimbursement shifts

Inspire Medical Systems appointed AtriCure CEO Michael H. Carrel to its Board as director Casey M. Tansey plans to retire. The company reported quarterly revenue of $200.58 million and earnings of $0.14 per share, exceeding analyst expectations despite a year-on-year decline. Inspire raised its full-year outlook and launched Project Horizon, targeting $30 million in annualised investment capacity for patient access and education. The initiative comes alongside proposed reimbursement increases for its Inspire 5 procedure in 2027. The company's revenue narrative projects $987.4 million revenue and $67.1 million earnings by 2029. Investors are weighing the impact of Project Horizon against ongoing reimbursement and coding volatility affecting the firm's implant-based approach to obstructive sleep apnea treatment.

Yahoo Finance
Aug 3rd, 2026
Inspire Medical beats Q2 estimates with $200.6M revenue, raises full-year guidance to $855M

Inspire Medical Systems reported second-quarter revenue of $200.6 million, beating analyst estimates by 3% despite a 7.6% year-on-year decline. The medical technology company, which develops implantable devices for obstructive sleep apnea treatment, posted adjusted earnings per share of $0.14, significantly exceeding the consensus estimate of -$0.25. The company raised its full-year revenue guidance to $855 million at the midpoint, 1.4% above analyst expectations. Management also increased full-year adjusted EPS guidance to $1.25, a 25% rise. Adjusted EBITDA reached $38.9 million with a 19.4% margin, beating estimates by 40.5%. Following the results, Inspire Medical Systems' stock jumped 13.6%. CEO Tim Herbert attributed the performance to increased discipline whilst navigating evolving coding and reimbursement challenges.

Yahoo Finance
Aug 2nd, 2026
Inspire Medical Systems Q2 revenue expected to drop 10.3% year on year

Inspire Medical Systems will report Q2 earnings on Monday after the bell. The medical technology company is expected to see revenue decline 10.3% year on year, a reversal from the 10.8% increase recorded in the same quarter last year. Last quarter, Inspire Medical Systems reported revenues of $204.6 million, up 1.6% year on year, beating analysts' expectations. However, the company's full-year revenue and EPS guidance missed estimates significantly. Analysts have generally reconfirmed their estimates over the last 30 days. Inspire Medical Systems shares are up 3.6% over the past month, trading at $51.21 against an average analyst price target of $51.43. Peers Bausch + Lomb and Baxter recently beat Q2 revenue expectations, with shares rising 2.7% and 5.7% respectively following their results.